Description

‍

FDA notice on Wegovy®/Ozempic® shortage: On February 21st, 2025, the U.S. Food and Drug Administration determined that the shortage of semaglutide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through April 22nd, 2025, from 503A compounding pharmacies and through May 22nd, 2025, from 503B compounding pharmacies. Beyond these dates, patients may explore personalized treatments and dosing options through BelleHealth to support their unique health and wellness goals.

‍

Why Belle

‍

• Best price on the market
• Medical oversight so you can talk to a nurse anytime you have questions
• Customized microdosing
• No BMI restrictions

Benefits of Semaglutide

‍

• Weight loss
  • Reduces appetite and slows digestion
  • Improves waist circumference and blood pressure
• Blood sugar control
  • Helps people with prediabetes revert to normal blood sugar levels
  • Improves glycated hemoglobin, fasting plasma glucose, and lipid profiles
• Cardiovascular health
  • Reduces the risk of major cardiovascular events, including heart attack and stroke
  • Lowers cardiovascular-related deaths
• Inflammation
  • Reduces inflammatory processes, which can help with diabetic complications
• Kidney health
  • May protect kidney health
  • Reduces the risk of major kidney disease events

‍